Salgo  
Coyne  

Martin  
Moe  

Medical Crossfire: An Expert Panel Debates Key Clinical Issues in Mineral Metabolism and Mortality in CKD.  (ASN Renal Week Official Symposium. November, 2005, Philadelphia, PA)
This is a bit of a novel format. First Drs. Coyne, Moe, and Martin each give a very brief overview of mineral metabolism in CKD, and then they launch into an hour discussion of vascular calcification, control of serum phosphorus, and audience questions, using the Medical Crossfire™ format. Coyne: What are the associations between Ca, Pi, their product, and PTH vs. mortality in ESRD and CKD? How is this modified by active vitamin D treatment? What is Ca absorption with the various Ca-containing binders? Moe: What are traditional and non-traditional risk factors controlling vascular calcification? How can calcium load and vitamin D affect vascular calcification? Martin: As renal function falls, how do Ca, Pi, and PTH change? How can we better understand Pi balance in CKD patients? What are the potential pitfalls and advantages of the various classes of Pi binders? Finally, as mentioned initially, the main thrust of this program is in the discussion sections, which are presented in both video and audio formats. (more...)


Updated: May 07, 2008 (M07)
M07 JASN: Calcitriol associated with a lower mortality in pre-ESRD patients.
M06 Abbott launches investigator-initiated grant program focusing on nonclassical actions of vitamin D receptors: App deadline June 30..
M05 CJASN July preview: Niacinamide effective as a phosphate binder.
M05 ASN Renal Week abstract archives 2003-2006 now available on-line in .pdf format.
A29 Thiazolidinediones (glitazones) may increase fracture risk in diabetics.
A23 CARE-2 study published on-line in AJKD. CAC progression with calcium acetate plus atorvastatin similar to sevelamer.
A17 Low serum 25D levels associated with incrased peripheral arterial disease risk.
A15 Archives Int Med: Loop diuretics associated with lower bone density in men.
A12 Once yearly zoledronic acid increases lumbar spine density by 4% in glucocorticoid-induced osteoporosis patients; better than risedronate
A12 Artificial reef approach to strengthening bone.
A11 Shire Pharma launches On Track phosphate binder adherence toolkit.
A09 JASN early release: Raloxifene increases bone mineral density in CKD patients.
A06 Teriparatide (Forteo) gets European regulatory approval for treatment of glucocorticoid-induced osteoporosis.
M15 Bile acid derivatives shown to strongly activate the VDR receptor without increasing calcium.
M13 JASN early release: Both low and high 1,25 D levels associated with vascular calcification in kids.
General Advances Emphasis
archive
Contemporary Diagnosis and Treatment of Vitamin D-Related Disorders ASBMR 2006
Clinical implications of bone biopsy ASN Renal Week 2006 (audio only)
Magnesium Balance: Hypomagnesemia and Hypermagnesemia (Coyne) ASN Board Review 2006
Low Bone Turnover Disease: Consequences, Prevalence, Detection and Treatment (Thomas L. Cantor, BA; Hassan Fehmi, MD; Gerard M. London, MD; Simon Waller, MD, MBBS, BSc) ADC 2006 (audio only)
Update on Vascular Calcification in Chronic Kidney Disease (CKD) Patients (Isaac Teitelbaum, MD; Robert Toto, MD; Dennis Andress, MD; Gerard M. London, MD) ADC 2006 (audio only)
Newer Approaches to Renal Osteodystrophy in Chronic Kidney Disease Patients (London, Sprague, Coyne, Goodman, Wolf) ADC 2006 (audio only)
Managing Renal Osteodystrophy: Discussion of Interesting Cases (Sprague, Moe) ASN Renal Week 2005 (audio only)
Active Vitamin D Therapeutic Options: Links to Cardiovascular Outcomes in the Management of CKD (Wolf, Llach) ASN Renal Week 2005 (audio only)
Atherosclerosis and Vascular Calcification in CKD (Hruska, Vanholder, Himmelfarb) ASN Renal Week 2005 (audio only)
Strategies for Reducing Parathyroid Hyperplasia, Fractures and the Need for Parathyroidectomy in Renal Disease (Fukagawa, Cunningham) ASN Renal Week 2005 (audio only)
Advances in the Treatment of Renal Osteodystrophy (Goodman, Sprague) ASN Renal Week 2005 (audio only)
Controversies in Managing Hyperphosphatemia in CKD and ESRD (Young, Rosas, Goldfarb) ASN Renal Week 2005 (audio only)
Stones and Bones (Coe, Kramer, Thakker) ASN Renal Week 2005 (audio only)
Recent Advances in Regulation of Calcium, Magnesium and Phosphate Homeostasis and Metabolism (Murer, Konrad, Huang, Weinman) ASN Renal Week 2005 (audio only)
An Expert Panel Debates Key Clinical Issues in Mineral Metabolism and Mortality in CKD (Medical Crossfire) (Coyne, Moe, Martin) ASN Renal Week 2005
Case Discussions: Disorders of Calcium Metabolism (Bushinsky, Andress) ASN Board Review 2005
The Role of Vitamin D in CKD (Slatopolsky, Sprague, Thadhani) ADC 2005 (audio only)
Calciphylaxis (Bleyer) ASN Renal Week 2004
Bones, Moans, and Groans: Skeletal Disorders in Chronic Kidney Disease Part 1 of 2. (Alleman) ANNA
Bones, Moans, and Groans: Skeletal Disorders in Chronic Kidney Disease Part 2 of 2. (Alleman) ANNA
Mineral and Bone Treatment Options for the Stage 3 and 4 CKD Patient (Lindberg) ASN 2004
The Essential Role of Vitamin D in the Pathophysiology of CKD (Jones) ASN 2004
Mineral and Metal Accumulation Without Changes in the "Usual Laboratory Suspects": How to Detect and Manage such Patients (Moe) ASN 2004
Tissue and Vascular Calcification: Clinical Overview and Detection (Raggi) ASN 2004
Coronary Artery Calcification: Scanning Methods and Clinical Results in the General Population (Rumberger)

Hidden Phosphorus: Where Do We Go From Here? (Murphy-Gutekunst L) J Ren Nutr (Jul 07)
Hypomagnesemia in patients with type 2 diabetes CJASN 03-07
Metabolic bone disease in chronic kidney disease JASN 03-07
ACCF/AHA 2007 Clinical Expert Consensus Document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain. Circulation (02-07)
Calcific uremic arteriolopathy: advances in pathogenesis and treatment Semin Dial 04-07
Pathogenesis and prevention of bone loss in patients who have kidney disease and receive long-term immunosuppression. JASN (01-07)
Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. (A. Levin et al) Kidney Int 01-07
Bone Disease Links
NKF-K-DOQI
K-DOQI Homepage
K-DOQI Bone Guidelines

General
Bone Physiology (Dr. Ott)
Renagel Patient Assistance
ESRD 11 Bone med protocols
HDCN Topic Pages (KEY)
Bone Disease
Hypercalcemia
Hypocalcemia
Hypermagnesemia
Hypomagnesemia